ANNONCE

PRM / LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma

2. marts 2020 12:05 | Af: Ritzau Info
 

Pressemeddelelse fra LEO Pharma

Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 MEUR has been completed. The initial agreement with Karo Pharma was announced on December 23, 2019 and approved by relevant competition authorities on February 20, 2020.

This divestment marks an important step for LEO Pharma towards strategically aligning its portfolio and increasing focus on innovation and dermatology.

The divested products include four anti-hemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology products, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®).

Kontakt:

Maia Fredtoft Søchting
Global External Communications
+45 26814579
mfddk@leo-pharma.com

Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/leo-pharma-group-completes-divestment-of-emollients-and-proctology-portfolio-to-karo-pharma?releaseId=13589164

** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **

ANNONCE

ANNONCE
Del din kommentar
Forsiden lige nu